Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECREJARY OF THE SENATE 99 MIG 12 PH IZ: 49 H. O.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Registrant Name		
Fox, Bennett & Turner	777-P;PP;	
Address Check if different than previously reported 750,17th Street, N.W., Suite 1100, Wash:		
Principal Place of Business (if different from line 2)	Marrell-1141	L1740PLL 01L017177777777777 127L10F640F777100F747777777
City: State/Z	Zip (or Country)	-11-1-1- 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-
. Contact Name Telephone	E-mail (optional)	5. Senue ID #
Albert Cacozza (202) 778-2300	#F&W.4#FW.7#FF177FFF177F614466146661##FW77#FFFF1777FFF1177FFF1	15270-191
. Client Name Self		6. House ID #
Novartis Pharmaceuticals Corporation		
YPE OF REPORT 8. Year 1999 Midyean	r (January 1-June 30) 🖾 OR Y	ear End (July 1-December 31)
Check if this filing amends a previously filed version of this	N	
). Check if this is a Termination Report 🔲 🗢 Termination	Date	11. No Lobbying Activity
INCOME OR EXPENSES - Complete Either	Line 12 OR Line 13	**************************************
12. Lobbying Firms	· 13. Orga	nizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying period were:	activities for this reporting
Less than \$10,000 🖾	Less than \$10,000 🖸	
2000 1110 1110 1110	\$10,600 or more 🖸 🗢 \$	
\$10,000 or more		Expenses (nextest \$20,000)
income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000,	14, REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
of all lobbying related income from the client (including all	Method A. Reporting amounts using LDA definitions only	
payments to the registrant by any other entity for lobbying activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(B)of the Internal Revenue Code	
	Method C. Reporting amou	
	internal Revenu	e Code
Signature		
Printed Name and Title		

	essary to reflect the general issue areas in which the registran porting period. Using a separate page for each code, provid ecded.	
15. General issue area code HCR (one per page	e)	
16. Specific lobbying issues		
17. House(s) of Congress and Federal agencies contacte	ed Check if None	
	•	
18- Name of each individual who acted as a lobbyist in	this issue area	
. Name	Covered Official Position (if applicable)	Nev
<u>:</u>		
AAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	A STATE OF THE STA	
		<u>-</u>
		-
		l D
		0
19. Interest of each foreign entity in the specific issues listed the degree that public policies, either lagraceuticals Corp., so too Novartis AG wil	ws or regulations, commercially benefit Novart I benefit. Novartis AG is the parent company benefits in the commercial success of its sub	of
19. Interest of each foreign entity in the specific issues listed the degree that public policies, either laarmaceuticals Corp., so too Novartis AG will vartis Pharmaceuticals Corp. and the parent	ws or regulations, commercially benefit Novartal benefit. Novartis AG is the parent company benefits in the commercial success of its subsense Date	tis of

5. General issue a	area code MED (one	per page)	
Specific lobby	ing issues		
	January Commencer		
7. House(s) of C	ongress and Federal agencies	contacted	
	Ť	•	
R. Name of each	individual who acted as a lob	Thuist in this issue area	
18. Name of each	individual who acted as a lob		l No
18. Name of each		Divist in this issue area Covered Official Position (if applicable)	N
18. Name of each		Covered Official Position (if applicable)	
18. Name of each	Name .	Covered Official Position (if applicable)	
18. Name of each	Name .	Covered Official Position (if applicable)	
18. Name of each	Name .	Covered Official Position (if applicable)	C
18. Name of each	Name .	Covered Official Position (if applicable)	
18. Name of each	Name .	Covered Official Position (if applicable)	
18. Name of each	Name .	Covered Official Position (if applicable)	
19. Interest of each	Name Name	Covered Official Position (if applicable) Sues listed on line 16 above	
19. Interest of each the degree that maceuticals (Name a foreign entity in the specific isset public policies, eit public, so too Novartis	Covered Official Position (if applicable)	C C C

OBBYING ACTIVITY. Select as many codes as necessangaged in lobbying on behalf of the client during the report information as requested. Attach additional page(s) as need.	ing period. Using a separate page for each code, prov	
15. General issue area code(one per page)		
16. Specific lobbying issues		
and the second s		
17. House(s) of Congress and Federal agencies contacted	Theck if None	
,		
18. Name of each individual who acted as a lobbyist in this	issue area	
. 18. Name of each individual who acted as a lobbyist in this Name	issue area Covered Official Position (if applicable)	Ne
		Ne Q
		0
		0
Name	Covered Official Position (if applicable)	0
Name	Covered Official Position (if applicable)	
Name	Covered Official Position (if applicable)	
Name	Covered Official Position (if applicable)	
Name	Covered Official Position (if applicable)	
Name	Covered Official Position (if applicable) Line 16 above	